Silence Therapeutics says Phase 2 SANRECO trial meets primary endpoint for divesiran in polycythemia vera

Reuters2026/08/10 11:30

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Silence Therapeutics reported positive topline Phase 2 SANRECO results for divesiran in phlebotomy-dependent polycythemia vera, supporting a best-in-class positioning.
The trial met its main efficacy goal, showing most treated patients maintained hematocrit control without needing phlebotomy versus placebo.
Secondary measures also improved, including reduced phlebotomy use, better iron markers, and symptom scores.
Safety was consistent with earlier studies, with no new safety signals reported.
Full data will be presented at a future medical congress; Phase 3 development is planned.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silence Therapeutics plc published the original content used to generate this news brief via Business Wire (Ref. ID: 20260810915756) on August 10, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Silence Therapeutics says Phase 2 SANRECO trial meets primary endpoint for divesiran in polycythemia vera

You may also like

Crypto prices